Novel therapy for children with chronic hormone deficiency provides lifeline for parents
- Alkindi® is the first replacement therapy specially designed for infants, children and adolescents with paediatric adrenal insufficiency
- Adrenal insufficiency is caused by a lack of the stress hormone cortisol – which can be fatal
- This new therapy, which has been developed by University of Sheffield spin-out company Diurnal, has been granted market authorisation by the European Medicine Agency.
Recent Blog Posts
What you should know about COVID-19 – updated 10th August 2021
Guidance from other organizations is continually being issued and we'll do our best to link to them below - please keep checking back here for more updates. UPDATE 10th August 2021 Article: “ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises”...
Genomics England – The Generation Study – CAH included
The Generation Study is being carried out by Genomics England in partnership with the NHS. It is exploring the possible use of genome sequencing in newborn babies to identify a wide range of rare genetic conditions alongside the routine newborn blood spot screening....
2024 CAH Support Group Conference, 9th June, Tamworth
SUNDAY 9 JUNE 2022 9.30 -16:00 DRAYTON MANOR RESORT, TAMWORTH, B78 3TW www.draytonmanor.co.uk Those living with CAH and their families and friends are invited to the biennial conference of CAH Support Group. Visit our online booking page here to find out more or book...
Online Meeting for Adults with CAH – 3rd February 2024, 10:30-12:30 UK time
This is an opportunity to meet other adults with CAH in a safe and supportive environment, where we share experiences, learn about current developments and have the opportunity to socialise with others in the CAH community. We're pleased to announce that we'll be...